A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.
Withdrawn · Phase 4 · NCT06390111
Conditions: Bladder Cancer, Ta/T1, CIS
At a glance
- Research payments reported, 2025
- $82,067
- U.S. investigators named
- 4
- Sites paid
- 4
About the trial
- Sponsor
- Ferring Pharmaceuticals
- Tested
- nadofaragene firadenovec (drug)
- Dates
- Started 2024-06-17; completion 2026-07-31
- Results posted
- Not yet
In this phase 4 trial (000439), subjects with NMIBC CIS (± high-grade Ta/T1) who have not responded to their first dose of nadofaragene firadenovec (commercial ADSTILADRIN received before trial entry) will be offered reinduction when entering the trial.
From ClinicalTrials.gov, last updated 2024-11-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ferring Pharmaceuticals As reported $82,067 in research payments for this study in 2025 (6 payments).
Products named: Adstiladrin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Shreyas Joshi, M.D. Urology · Atlanta, GA
- Ralph J. Henderson, M.D. Urology · Shreveport, LA
- Alexander I. Sankin Urology · New York, NY
- Amy Luckenbaugh, MD Urology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Biomedical Research Alliance of New York LLC $37,420
- Emory University Hospital, GA $30,051
- Vanderbilt University Medical Center, TN $9,596
- Arkansas Urology Research Center LLC $5,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.